MIAMI & BARRANQUILLA, Colombia / Oct 02, 2023 / Business Wire / Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will host a webinar dedicated to the Colombian pharma market and its regulations on October 10th.
The Company will host a webinar at 10:00 a.m. Eastern time with Mariana Sarasti, Director of Pharmaceutical Industry Chamber within the National Business Association of Colombia (ANDI).
Mariana is an economist from The Chicago University, with a specialization in social economics from Universidad de los Andes and a master’s degree in public administration from Harvard University. She has extensive experience in business development and strategy, as well as in project planning and management in the public and private sectors.
To access the webinar, please use the following information:
Date: | Tuesday, October 10, 2023 |
Time: | 10:00 a.m. ET |
Webinar Link: |
The webinar will be broadcast live and available for replay via the investor relations section of Procaps’ website here.
About Procaps Group
Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.
For more information, visit Procaps’ investor relations website investor.procapsgroup.com.
Last Trade: | US$2.64 |
Daily Change: | 0.13 5.18 |
Daily Volume: | 35,054 |
Market Cap: | US$297.840M |
December 20, 2024 December 03, 2024 June 28, 2024 December 26, 2023 November 29, 2023 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB